|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM28658722X |
| 003 |
DE-627 |
| 005 |
20250223200906.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2018.07.006
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0955.xml
|
| 035 |
|
|
|a (DE-627)NLM28658722X
|
| 035 |
|
|
|a (NLM)30017909
|
| 035 |
|
|
|a (PII)S1521-6616(18)30410-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Salma, Nafai
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.08.2019
|
| 500 |
|
|
|a Date Revised 14.08.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2018 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Patients with antiphospholipid antibodies (APLA) are predisposed to develop thrombosis, however the standardization of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein I (β2-GPI) Ab assays are challenging. Therefore we decided to test the performance of a new chemiluminescent assay (CLIA), and assayed aCL and aβ2-GPI IgG/M in serum from 120 healthy individuals, 108 patients with idiopathic venous thrombosis, 78 patients with antiphospholipid syndrome (APS), and 64 non-thrombotic APLA-carriers using CLIA IDS-iSYS. Very good (aCL/aβ2-GPI IgG) to moderate (aCL/aβ2-GPI IgM) agreement with a commercial and an in house ELISA assay were observed and, in particular, CLIA demonstrated the highest sensitivity in aβ2-GPI IgG detection. Finally, aCL/aβ2-GPI Ab capacity to predict the thrombotic risk was tested showing for CLIA a significant odds ratio (OR) when considering double positivity for aCL/aβ2-GPI IgG, aCL IgG at high levels, and aβ2-GPI IgG at high levels. In conclusion, CLIA improves aβ2-GPI IgG detection and thrombotic risk assessment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Anti-cardiolipin
|
| 650 |
|
4 |
|a Anti-phospholipid syndrome
|
| 650 |
|
4 |
|a Anti-β2GPI
|
| 650 |
|
4 |
|a Chemiluminescence
|
| 650 |
|
4 |
|a Thrombosis
|
| 650 |
|
7 |
|a Antibodies, Anticardiolipin
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Antiphospholipid
|2 NLM
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a Cardiolipins
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a beta 2-Glycoprotein I
|2 NLM
|
| 700 |
1 |
|
|a Julie, Lemerle
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Boutahar, Bendaoud
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sylvie, Le Nuz
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Eleonore, Bettacchioli
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fabien, Le Ny
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Elisabeth, Pasquier
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sandrine, Jousse-Joulin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Francis, Couturaud
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sophie, Hillion
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yves, Renaudineau
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 194(2018) vom: 15. Sept., Seite 92-99
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:194
|g year:2018
|g day:15
|g month:09
|g pages:92-99
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.07.006
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 194
|j 2018
|b 15
|c 09
|h 92-99
|